---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-301836"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2022-12-09T23:59:59+00:00"
generated_at: "2026-06-21T06:57:46.408603+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics amends bylaws for universal proxy rules and DGCL updates

## Summary
- Enhanced disclosure requirements for stockholder nominations, including questionnaires and nominee resignation agreements.
- Added provisions for Universal Proxy Rules (Rule 14a-19), requiring intent disclosure and evidence of compliance.
- Clarified board authority to determine if nominations/proposals properly brought and to postpone/cancel meetings.
- Updated provisions for remote meetings and adjournment procedures per recent DGCL amendments.

## SEC filing metadata
- accession: 0001193125-22-301836
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2022-12-09T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312522301836/0001193125-22-301836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312522301836/d514100d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-301836
- JSON: https://secwatch.observer/filing/0001193125-22-301836.json
- Plain text: https://secwatch.observer/filing/0001193125-22-301836.txt

## Key facts
- Governance Changes
  Sensei Biotherapeutics, Inc.: Adopted amended and restated bylaws effective December 5, 2022, updating procedural mechanics, disclosures, universal proxy rules, and other conforming changes (effective 2022-12-05).
  - Change: bylaw amendment
  - Effective: 2022-12-05
  source text: On December 5, 2022, in connection with the new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”) and a periodic review of the bylaws of Sensei Biotherapeutics, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) adopted amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312522301836/0001193125-22-301836-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.